Business in Brief: Teva Unfazed as U.S. Approves Second Generic Rival for Copaxone

Gilat finally swings to profit ■ Leumi turns bearish on Leviathan ■ Stocks end mixed

Send in e-mailSend in e-mail
Teva Pharmaceutical Industries factory in Jerusalem, December 17, 2017
Teva Pharmaceutical Industries factory in Jerusalem, December 17, 2017Credit: Tsafrir Abayov/AP

Comments